Pfizer, BioNTech vaccine neutralises Omicron with three shots

BioNTech and Pfizer (PFE.N) said on Wednesday a three-shot course of their COVID-19 vaccine was able to neutralise the new Omicron variant in a laboratory test and they could deliver an upgraded vaccine in March 2022 if needed.

The German and U.S. companies said two doses of their vaccine resulted in significantly lower neutralising antibodies but a third dose boosted those antibodies by a factor of 25.

“The first line of defence, with two doses of vaccination, might be compromised and three doses of vaccination are required to restore protection,” BioNTech Chief Medical Officer Ozlem Tuereci said at a press conference. The companies suggested that two doses may still protect against severe disease.

BioNTech and Pfizer are the first manufacturers of a COVID vaccine to issue an official update on the efficacy of their shot against Omicron.

In samples of blood taken around a month after the third shot the Omicron variant was neutralised about as effectively as two doses neutralised the original virus identified in China.

BioNTech CEO Ugur Sahin suggested that countries might consider shortening the time period between second and third doses of the vaccine to combat the new variant.

He cited recent moves by countries including Britain to bring the third shot forward to three months after the second shot, from six months previously.

“We believe this is the right way to go particularly if the Omicron is now spreading further, to enable a better level of protection in the winter season,” Sahin said.

The Omicron variant, first detected in southern Africa and Hong Kong last month, has triggered global alarm about another surge in infections. Cases have already been reported from Japan to the United States and across Europe.

The World Health Organization classified Omicron on Nov. 26 as a “variant of concern” but said there was no evidence to support the need for new vaccines specifically designed to tackle the variant and its mutations.

Nevertheless, the companies said they would continue efforts to bring an Omicron-specific COVID-19 vaccine to market. Work started when the variant first raised concern on Nov. 25.

They said their planned production of 4 billion doses of the Comirnaty vaccine in 2022 was not expected to change if an adapted vaccine was required.

The findings are broadly in line with a preliminary study published by researchers at the Africa Health Research Institute in South Africa on Tuesday, which said Omicron could partially evade protection from two doses of the Pfizer/BioNTech vaccine and suggested a third shot might help fend off infection.

Research on the new variant is still at an early stage. Laboratory analysis at University Hospital Frankfurt in Germany found the ability to mount an antibody response to Omicron in people who had three shots was up to 37 times lower than the response to Delta.

“The companies believe that vaccinated individuals may still be protected against severe forms of the disease,” BioNTech and Pfizer said.

The vast majority of surface structures on the Omicron spike protein targeted by the T-cells, which typically emerge after vaccination, are not affected by Omicron’s mutations, they said.

T-cells are the second pillar of an immune response, alongside antibodies, and are believed to prevent severe disease by attacking infected human cells.

For their analysis, the two companies used a virus that was bio-engineered to have the hallmark mutations of Omicron, known as a pseudovirus, and blood was collected from subjects three weeks after a second vaccine dose or one month after a third.

There is no significant data yet on how vaccines from Moderna (MRNA.O), Johnson & Johnson (JNJ.N) and other drugmakers hold up against the new variant but they are expected to release their own data within weeks.